Trials / Completed
CompletedNCT06183047
Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Military Institute od Medicine National Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT). | early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT). |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
- First posted
- 2023-12-27
- Last updated
- 2023-12-27
Source: ClinicalTrials.gov record NCT06183047. Inclusion in this directory is not an endorsement.